Peptide profile
ACE-031
ACVR2B-Fc myostatin/activin trap
Compare ACE-031 with other peptides →Summary
A man-made protein that blocks signals telling muscles to stop growing.
- Typical dose
- 1-2mg 1x weekly
- Route
- Subcutaneous
- Cycle length
- 4-8 weeks
- Evidence
- Anecdotal
Mechanism
How it works
ACE-031 is like a fake power outlet — it attracts myostatin and activins with the right plug but doesn't supply any electricity, so they can't activate muscle growth brakes.
ACVR2B-Fc is a decoy receptor that binds myostatin and activins with high affinity, preventing them from activating the native ActRIIB receptor.
Reported in research
Benefits
- Blocks myostatin and activin, the muscle 'stop' signals
- Could lead to very big muscle growth
- Made animals grow more muscle in tests
Context, not a prescription
Dosing
- Typical range
- 1-2mg 1x weekly (Subcutaneous)
- Cycle length
- 4-8 weeks
Safety
Side effects & contraindications
Possible side effects
- Severe injection site reactions
- Fatigue
- Gum bleeding
- Tendon rupture
- Cardiac hypertrophy
- Severe immune reactions
Contraindications
- Pregnancy or breastfeeding
- History of bleeding disorders
- Cardiac disease
- Active cancer
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
It could make muscles grow a lot, but it is risky. Tests were stopped because of bleeding and skin marks.
How it works
ACE-031 is like a fake power outlet. The muscle 'stop' signals plug in but get no power. So they can't push the brakes on muscle growth.
It catches the muscle 'stop' signals outside your cells. This stops them from talking to muscle cells.
What to expect
Unknown in people. In animals, effects showed up in 2 to 4 weeks.
- Weeks 1-2: Muscles may feel full. You might feel tired.
- Weeks 2-4: Watch closely for any bleeding or gum problems.
- Weeks 4-6: Biggest effect. Stop right away if side effects show up.
Good to know
- Better not to use it. It is very unsafe.
- No safe plan has been found for people.
- Watch for heart trouble or bleeding signs.
Staying safe
- Bad reactions where the shot goes in
- Feeling very tired
- Bleeding gums
Avoid if you have:
- Pregnant or breastfeeding moms
- People who bleed easily
- People with heart problems
- People with cancer right now
Mechanism of action
ACVR2B-Fc is a decoy receptor that binds myostatin and activins with high affinity, preventing them from activating the native ActRIIB receptor.
Neutralizes extracellular myostatin and activins, preventing them from signaling through ActRIIB on muscle cells.
Pharmacodynamics
Unknown in humans; animal models show effects within 2-4 weeks.
Potential dramatic muscle growth but with significant risk profile. Clinical trials halted due to bleeding and skin lesion side effects.
Timeline
- Weeks 1-2: Potential muscle fullness and fatigue.
- Weeks 2-4: Monitor for bleeding or gum issues.
- Weeks 4-6: Maximum effect — discontinue if side effects appear.
Comparisons
- ACE-031 — effectiveness Unknown, safety Poor, cost $$$, Hard to use
- Follistatin-344 — effectiveness Unknown, safety Poor, cost $$$, Hard to use
Adverse effects
Common:
- Severe injection site reactions
- Fatigue
- Gum bleeding
Rare:
- Tendon rupture
- Cardiac hypertrophy
- Severe immune reactions
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- History of bleeding disorders
- Cardiac disease
- Active cancer
- Avoid use — safety profile is very poor
- No established safe protocol in humans
- Monitor for cardiac and bleeding symptoms
Qué hace
Podría hacer que los músculos crezcan mucho, pero es arriesgado. Las pruebas se detuvieron debido al sangrado y las marcas en la piel.
Cómo funciona
ACE-031 es como un enchufe falso. Las señales de 'parada' muscular se conectan, pero no reciben energía. Por lo tanto, no pueden frenar el crecimiento muscular.
Atrapa las señales de 'parada' muscular fuera de tus células. Esto evita que se comuniquen con las células musculares.
Qué esperar
Desconocido en personas. En animales, los efectos aparecieron en 2 a 4 semanas.
- Semanas 1-2: Los músculos pueden sentirse llenos. Podrías sentirte cansado.
- Semanas 2-4: Vigilar de cerca cualquier signo de sangrado o problemas en las encías.
- Semanas 4-6: Efecto máximo. Detener de inmediato si aparecen efectos secundarios.
Bueno saber
- Es mejor no usarlo. Es muy inseguro.
- No se ha encontrado un plan seguro para las personas.
- Vigilar signos de problemas cardíacos o sangrado.
Manteniéndose seguro
- Reacciones malas en el lugar de la inyección
- Sentirse muy cansado
- Sangrado de encías
Evitar si tienes:
- Mujeres embarazadas o en lactancia
- Personas que sangran fácilmente
- Personas con problemas cardíacos
- Personas con cáncer actualmente
Mecanismo de acción
ACVR2B-Fc es un receptor señuelo que se une a la miostatina y a las activinas con alta afinidad, impidiendo que activen el receptor ActRIIB nativo.
Neutraliza la miostatina y las activinas extracelulares, impidiendo que envíen señales a través de ActRIIB en las células musculares.
Farmacodinamia
Desconocido en humanos; los modelos animales muestran efectos en 2-4 semanas.
Potencial crecimiento muscular drástico, pero con un perfil de riesgo significativo. Los ensayos clínicos se detuvieron debido a efectos secundarios de sangrado y lesiones en la piel.
Cronología
- Semanas 1-2: Posible sensación de plenitud muscular y fatiga.
- Semanas 2-4: Vigilar signos de sangrado o problemas en las encías.
- Semanas 4-6: Efecto máximo: suspender si aparecen efectos secundarios.
Comparaciones
- ACE-031 — efectividad Desconocida, seguridad Mala, costo $$$, Difícil de usar
- Follistatina-344 — efectividad Desconocida, seguridad Mala, costo $$$, Difícil de usar
Efectos adversos
Comunes:
- Reacciones graves en el sitio de inyección
- Fatiga
- Sangrado de encías
Raros:
- Rotura de tendón
- Hipertrofia cardíaca
- Reacciones inmunitarias graves
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Antecedentes de trastornos hemorrágicos
- Enfermedad cardíaca
- Cáncer activo
- Evitar su uso: el perfil de seguridad es muy deficiente
- No existe un protocolo seguro establecido en humanos
- Vigilar síntomas cardíacos y de sangrado
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 4-8 weeks
FAQ
Common questions
Why was ACE-031 discontinued?
Clinical trials were halted due to telangiectasias (skin lesions) and bleeding gums in participants.
Is ACE-031 legal?
No, it is an investigational drug not approved for any use. It is banned by WADA.
What is the evidence level?
This compound is classified as Anecdotal. Evidence relies primarily on self-reported user experiences. Controlled studies are lacking.
Research
Research & sources
Current evidence for ACE-031 is rated as Anecdotal. No controlled clinical research is available.
- 1. ACE-031 clinical trial (2011) — DOI:10.1016/j.nmd.2011.06.1023
- 2. Myostatin inhibition therapies (2008) — DOI:10.1172/JCI37552
- 3. ACE-031 clinical trial (2011)
- 4. Myostatin inhibition therapies (2008)